Loading
A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by TORL Biotherapeutics, LLC, now recruiting.
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer is a phase 1/2 interventional study registered as NCT07322094 by TORL Biotherapeutics, LLC, with 60 participants planned, started 2025-12-10 and due to reach its primary completion in 2027-12. Interventions recorded: TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin. Conditions listed: FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/